title: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation.
abstract: This article demonstrates a case of a lung adenocarcinoma patient in stage IV harboring an epidermal growth factor receptor (EGFR) 19 exon deletion mutation treated with 500 mg/m2pemetrexed and 75 mg/m2cisplatin on day 1, sequenced with 250 mg gefitinib on prescription on days 4-28 for six cycles as first-line, then by gefitinib combined with pemetrexed as maintenance therapy. The patient achieved a partial response. Performance status increased from grade 2 to 1. The progression-free survival period was 17 months. Overall survival is now over three years. Side effects of grade two liver dysfunction and dermal toxicity were tolerable. Combined gefitinib with platinum-based chemotherapy as first-line treatment probably benefits non-small cell cancer patients in stage IV harboring sensitive EGFR gene mutations with a better local control rate, longer survival, and tolerable side effects.
authors.affiliation: Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
authors.forename: Aimi
authors.initials: A
authors.lastname: Huang
authors.affiliation: Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Li
authors.affiliation: Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
authors.forename: Jikai
authors.initials: J
authors.lastname: Zhao
authors.affiliation: Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
authors.forename: Xiaofei
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Jin
authors.affiliation: Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
authors.forename: Yanjie
authors.initials: Y
authors.lastname: Niu
authors.affiliation: Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
authors.forename: Liyan
authors.initials: L
authors.lastname: Jiang
authors.affiliation: Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
authors.forename: Baohui
authors.initials: B
authors.lastname: Han
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D018450:Disease Progression; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D009362:Neoplasm Metastasis; D000068437:Pemetrexed / Q000008:administration & dosage / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000068437:Pemetrexed; C512478:EGFR protein, human; D066246:ErbB Receptors; D002945:Cisplatin; D000077156:Gefitinib
keywords: Chemotherapy; EGFR sensitive; mutation; non-small cell lung cancer; target therapy